The role of aberrant DNA methylation in cancer initiation and clinical impacts is a research paper published in Therapeutic Advances in Medical Oncology (2024). On theSindex it has a DataRank of 0. It has been cited 94 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Health and Medical Research Council
Grant: GNT2008631
National Health and Medical Research Council
Grant: GNT2009783
Swiss Cancer Research Foundation
Grant: KFS-5445-08-2021
NIH NCI
Grant: R01 CA237600
NIH NCI
Grant: R01 CA251817
National Institutes of Health
Grant: 5R01CA237600-02
Combined Methylation and Mutation to Predict Response to PARP Inhibitors
National Institutes of Health
Grant: 5R01CA251817-03
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
FWCI
15.54
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals